Literature DB >> 1862056

Premenopausal determinants of menopausal estrogen use.

G M Egeland1, L H Kuller, K A Matthews, S F Kelsey, J Cauley, D Guzick.   

Abstract

METHODS: Characteristics related to subsequent use of estrogen replacement therapy were evaluated prospectively in a cohort of 541 healthy premenopausal women being followed through the menopausal transition.
RESULTS: Among women who became menopausal during the follow-up period, the most striking premenopausal baseline differences between menopausal estrogen users and never users were that users tended to be thinner and more likely to report past oral contraceptive use than never users (P less than or equal to 0.05). Nonsignificant trends were also observed, with menopausal estrogen users having higher total high-density lipoprotein cholesterol and lower fasting insulin prior to estrogen use than the menopausal never users (P less than or equal to 0.10). Weaker trends included greater alcohol intake and past week kilocalorie expenditure and lower blood pressure levels among menopausal estrogen users than never users.
CONCLUSIONS: Although these findings do not preclude the probable protective effect of estrogen therapy on coronary heart disease morbidity and mortality, they do suggest that slightly healthier women may take menopausal hormones.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1862056     DOI: 10.1016/0091-7435(91)90033-z

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  7 in total

1.  Why do women doctors in the UK take hormone replacement therapy?

Authors:  A J Isaacs; A R Britton; K McPherson
Journal:  J Epidemiol Community Health       Date:  1997-08       Impact factor: 3.710

Review 2.  Postmenopausal hormone replacement therapy, coronary heart disease and plasma lipoproteins.

Authors:  M Seed
Journal:  Drugs       Date:  1994       Impact factor: 9.546

3.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group.

Authors:  J A Kanis
Journal:  Osteoporos Int       Date:  1994-11       Impact factor: 4.507

4.  Using predictors of hormone therapy use to model the healthy user bias: how does healthy user status influence cognitive effects of hormone therapy?

Authors:  Carey E Gleason; N Maritza Dowling; Elliot Friedman; Whitney Wharton; Sanjay Asthana
Journal:  Menopause       Date:  2012-05       Impact factor: 2.953

5.  Early initiation of hormone therapy in menopausal women is associated with increased hippocampal and posterior cingulate cholinergic activity.

Authors:  Yolanda R Smith; Luvina Bowen; Tiffany M Love; Alison Berent-Spillson; Kirk A Frey; Carol C Persad; Nancy K Reame; Robert A Koeppe; Jon-Kar Zubieta
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

6.  Menopausal hormone therapy and sleep-disordered breathing: evidence for a healthy user bias.

Authors:  Anna G Mirer; Paul E Peppard; Mari Palta; Ruth M Benca; Amanda Rasmuson; Terry Young
Journal:  Ann Epidemiol       Date:  2015-08-06       Impact factor: 3.797

7.  Hormone replacement therapy: characteristics of users and non-users in a British general practice cohort identified through computerised prescribing records.

Authors:  T Lancaster; G Surman; M Lawrence; D Mant; M Vessey; M Thorogood; P Yudkin; E Daly
Journal:  J Epidemiol Community Health       Date:  1995-08       Impact factor: 3.710

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.